Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Par CEO replaced

Executive Summary

Patrick LePore takes over as president and CEO of Par Pharmaceutical following resignation of Scott Tariff at the request of the board of directors, the company announces Sept. 26. Executive chairman Mark Auerbach also steps down at board's request; former lead director John Abernathy will fill the role as non-executive chairman. LePore worked in sales and marketing at Roche from 1978 to 1984; in 2002, he oversaw the sale of medical communications company Boron LaPore & Associates to Cardinal Health. Par announced in July that it would be restating its financial results for 2004 through the first quarter of 2006, reducing Par's revenues over that time period by as much as $55 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel